This is a relatively detailed and informative interview with Umang Vohra of Cipla. Some of the interview questions are quite good. This interview actually gives one the sense of where CIpla is planning to go over the next few years.
2 Likes
Cipla: Beyond the pursuit of profit. This is an article on Cipla’s history and future.
With Goa plant also facing observations and now these 8 observations for Pithampur plant, will
Cipla find it difficult to launch Advair by April as earlier planned??
Since someone bought it up, I was actually wondering why a company like Cipla finds it so difficult to pass such inspections. Are they negligent, or are the inspections just extremely demanding? Or is there some other issue that I am not aware of?
Surely in the light of the importance of these inspections, the company should do everything it could to make sure it passed without issue?
Also, is this the reinspection (audit?) that is referred to in the earnings call quoted above? As in “So, up to FDA, like they might need to reinspect the plant”? If so, it seems that Umang Vohra was not expecting this?
1 Like
Good results by Cipla for Q4. Looks like it is well poised til 2025 with both India and USA biz seeing good traction. Only caveat is that FDA issues should be managed well and shouldn’t go out of control.
Cipla Q4 and FY 23 ending concall highlights -
Full yr results -
Sales - 22753 cr, up 5pc ( up 11 pc adjusted for COVID products )
EBITDA - 5027 cr, up 22 pc
PAT - 2984 cr, up 13 pc
Q4 results -
Sales- 5739 cr, up 9 pc
EBITDA- 1174 cr, up 20 pc
PAT- 708 cr, up 12 pc
In Q4 -
India business (branded generics+trade generics+OTC) grew 16 pc adjusted for COVID sales
US business sales at $ 201 million, up 27 pc
SAGA (South Africa+ Africa general)business de grew
in Q4
R&D at 371 cr, up 15 pc yoy. Currently at 6.5 pc of sales
India OTC sales crossed 1000cr in FY 23 (their return ratios, in some time will be better than any Indian FMCG business)
FY24 geography wise sales break up-
India-9869cr
North America-5909cr
SAGA ( SA + Subsaharan Africa)-3166cr
Intl Mkts ( Europe + RoW )-3028cr
APIs-134cr
India branded growth (ex Covid) grew 13 pc vs 8 pc Mkt growth
Chronic share in India business improved by 300 bps to 59 pc vs 56 pc YoY
21 Indian Brands in top 300. Each of these are 100 cr plus brands
In trade generics, there are 08 brands clocking 50 cr plus revenues
Have licensed Novartis’s Diabetic combination drugs(Galvus) that clocked 250 cr+ revenues last yr for India
Also entered into an agreement to market Scapho (injectable) … a monoclonal antibody used to treat psoriasis for India
Acquired Endura Mass for India consumer business
Added 800 MRs in India
Three complex generic products in pipeline. Filing to commence in FY 24
FY23 Gross Margins at 64 pc
ROIC for FY23 at 23 pc
EBITDA margins at 22 pc
Full yr EBITDA and ROIC includes high RM prices in first 8-9 months of FY23
Gross Debt at 783 cr
Should see significant growth in US business in FY 24. $ 190-200 million should be the trajectory for US base business. This translates to a sale of 6260-6560 cr annual sales vs 5909 cr in FY 23
India OTC business is skewed towards summer months
Expect Advair launch in 12+ months in US
All big products for US Mkts to be filed from 2 sites to de-risk the business
Investing heavily in respiratory and peptides portfolio for next 3 yrs
India business to see impact of price hikes taken by the company in Q1
Continue to be bullish on Galvus sales going fwd
Another 200 or so MRs to be added this year
Revlimid numbers are already in the company’s US business performance
Albuterol is growing well in US
Cipla holding 18 pc mkt share of Lanreotide Injection
Strong growth in Tier-2 to 6 towns in India specially in Respiratory and Anti-Infectives
Aim to hit 22 pc EBITDA margins in FY 24 as well
Simbicort Inhaler to be filed by Q4 of FY 24
Respiratory revenues from US at around 1400 cr range vs total US sales of 5900 cr
SAGA mkts to show some growth in FY 24 plus improved margins
Current cash balance around 5500 cr. Aim to invest most of this in India business
Disc: Hold a small tracking position… mostly for trading purposes unless US Mkt’s pricing pressures go away ( US, by the way is reporting highest drug shortages since 2012-13 ) or they end up acquiring some good India focussed Assets with the 5000 cr+ cash they have on the books
2 Likes
I understand that Cipla in not facing major pricing pressure due to niche portfolio. Any insights you got from con call regarding pricing pressure for Cipla portfolio.
There was no direct question on that. But their confidence on maintaining at least $ 190-200 million base US business did, in a way indicate that their portfolio is not facing too many pressures
Plus the drug shortages in US are at 10 yr high. So …maybe we can take a leap of faith here
2 Likes
Good set of numbers from Cipla
Revenue +14%
EBIDTA +25%
PAT +32%
US revenue run rate of 230M USD - Up 18%
2 Likes
CIPLA Ltd -
Q4 FY 24 results and concall highlights -
Revenues - 6163 vs 5739 cr, up 10 pc YoY
EBITDA - 1316 vs 1174 cr ( up 13 pc YoY, margins @ 21 vs 20 cr )
PAT - 932 vs 522 cr
R&D spends @ 444 cr, @ 7.2 pc of sales
Segment Wise revenue break up -
India - 2417 cr, up 7 pc
North America - 1876 cr, up 11 pc
South Africa - 560 cr, up 26 pc
EMs - 830 cr, up 5 pc
APIs - 190 cr, up 40 pc
Total Debt @ 560 cr
Cash on books @ 8270 cr. Company is open to inorganic growth initiatives
Investments made in FY 24 -
Acquired Actor Pharma in South Africa for 400 cr. It has a portfolio of branded generics and OTC brands in SA
Got into a marketing and distribution partnership with SANOFI to distribute 06 of their CNS brands in India
Acquired OTC brand portfolio of IVIA beauty and Astaberry in India for 130 cr
Company has 21 brands ( branded generics ) in top 300 brands in IPM. These brands have a turnover > 100 cr each
Company has a booming Speciality - InLicensing business with FY 24 sales @ 761 cr. Last 5 yr CAGR here has been @ 39 pc
In addition, company has 5 OTC brands with sales > 100 cr / yr. These are - Omnigel, Nicotex, Prolyte ORS, Cipladyne, Cofsils
North American product pipeline -
Respiratory pipeline - 05 assets filed assets in last 12 months. Going to file 02 more assets in next 12-15 months. Major launches expected in next 12-15 months
Peptides and Complex generics - 12 assets already filed. Going to file 08 more assets in next 1-2 yrs. Multiple launches expected over FY 25-27
505(b)(2) assets - have filed 02 assets. Launches expected in next 1-2 yrs
Company has reached no 1 spot in the prescriptions business in SA
In India, Chronic portfolio’s share is now at 61 pc. Chronic business has a far superior gross margin profile vs Acute business
Company has hit 20 pc mkt share in Lanreotide
( injectable peptide - a 505(b)(2) products )and 13 pc Mkt share in Albuterol ( complex generic - inhaler ) mkt
Guiding for an EBITDA margin band of 24-25 pc for FY 25
30 pc of company’s total revenues come from Respiratory products
Company has set up a manufacturing facility in China. Have got US FDA approval for the same. Have spent aprox 430 cr to set up that facility. Also looking to penetrate / expand into the Chinese market
Company is likely to see 2 more years of strong Revlimid sales ie FY 25, 26
Company’s Pitampur and Goa plants are yet to resolve their USFDA issues ( warning letters ). Once company resolves these regulatory issues, there could be significant bump up in the US business ( company expects Goa resolution and commencement of supplies only towards the end of FY 25 )
R&D expenses to continue to remain in the band of 6-7 pc of revenues
Disc: holding, biased, not SEBI registered
1 Like
[quote=“Mayank.mail, post:65, topic:34567”]
With Goa plant also facing observations and now these 8 observations for Pithampur plant, will
Cipla find it difficult to launch Advair by April as earlier planned
[quote/]
Could this be connected with the recent resignation of executive vice chairperson??
CIPLA ; The USFDA inspected Medispray Laboratories’ Goa facility (Jan 14-20, 2025) and issued one observation in Form 483. Medispray will address it promptly.
1 Like
Cipla Reports Strong Q3: Best-Ever Margin At 28%, US Sales Beat Estimates
Watch here - https://youtu.be/NDx7Hyy_lJU
2 Likes
Cipla’s Q3 Conference Call Highlights - Segregated in terms of challenges and opportunities for business
Business Opportunities
-
US Market Expansion:
- New Facilities & Products: Invested $100 million in US facilities (DPI, MDI, OSD) with filings for generic Advair, Abraxane, and a partnered inhalation asset. These launches (expected in H2 FY26) could offset Revlimid generic competition.
- Respiratory Leadership: Albuterol market share rose to 21%, and new approvals (e.g., Phytonadione Injectable) strengthen the portfolio. Future respiratory assets (Symbicort, peptide injectables) offer growth potential.
-
Geographic Diversification:
- EMEU & Africa Growth: Combined EMEU and One Africa businesses contributed 25% of revenue, with South Africa growing 21% in ZAR terms. Private market penetration and tender execution drove margins.
-
Consumer Health Momentum:
- Anchor Brands: Nicotex, Omnigel, and Cipladine maintained leadership. The segment saw strong traction, aided by acquisitions and distribution improvements.
-
Regulatory Progress:
- Goa Facility Clearance: US FDA’s VAI classification for Goa supports future launches. Medispray and Virgonagar inspections pending, but resolution could enable new approvals.
-
Financial Strength:
- Record Revenue & Margins: Quarterly revenue of ₹7,073 crores (8% YoY) and EBITDA margin of 28%. Net cash of ₹8,947 crores allows strategic investments or acquisitions.
Challenges
-
Supply Chain Disruptions:
- US Supply Issues: Lamivudine and Lanreotide supply disruptions impacted revenue. Partner-dependent Lanreotide resolution is critical for Q4 recovery.
-
Regulatory Risks:
- 483 Observations: Virgonagar (8 observations) and Medispray (1 observation) await FDA classification, risking delays in approvals or launches.
-
Delayed Key Launches:
- Advair & Abraxane: Postponed to H2 FY26 due to regulatory processes, delaying revenue from high-potential assets.
-
Pricing Pressures:
- US Market Erosion: High single-digit price erosion in some products (e.g., generics) despite stable respiratory pricing. Potential tariffs on Indian pharma exports add uncertainty.
-
Operational Execution:
- India Consumer Health Transition: Past disruptions from shifting products between divisions highlight execution risks. Ensuring stable growth in trade generics remains a focus.
-
Dependency on US Market:
- Revenue Concentration: US contributes ~25% of revenue. Supply/regulatory setbacks here disproportionately impact overall performance.
Strategic Outlook:
Cipla’s diversified portfolio, respiratory leadership, and strong cash position position it for growth. However, resolving supply bottlenecks, accelerating US launches, and managing regulatory risks are critical to sustaining momentum. The company’s focus on derisking manufacturing and expanding in high-margin markets (EMEU, consumer health) will be key drivers in FY26.
1 Like
#Management Insights & Future Outlook from Q3 Concall
Growth & Profitability:
- Scaling and automation driving margin expansion and profitability despite minimal price hikes
- EBITDA margin of 28% in Q3FY25 is not sustainable long-term due to seasonal factors
Cash Utilization:
- ₹9,000 crore cash reserve to be deployed in acquisitions, product in-licensing, and portfolio expansion .
- Exploring differentiated assets in the US and high-growth opportunities in India.
US Respiratory Market:
- Expecting three major product launches in the next 15–18 months.
- Market dynamics will significantly impact revenue, depending on competitor entries.
Semaglutide & Oligonucleotides:
- Semaglutide (GLP-1) launch is expected in 2026 , pending regulatory approvals in India.
- Oligonucleotides portfolio in the pipeline, targeting a 3–5 year launch timeline .
Revlimid & Future US Expansion:
- Revlimid exclusivity loss in Jan’26 will bring increased competition
- gAdvair, gAbraxane, and other inhalation assets are expected to drive US business post-Revlimid
Mounjaro (Tirzepatide) Partnership:
- Open for in-licensing with Lilly , but final decision rests with the innovator
US Tariff:
- Waiting for the US policy framework to set in and setting up facilities in the US
- Will act accordingly after understanding the economics of manufacturing products in the US and India
- About one-third of the pharmaceutical supply in the US comes from India
Slow-Down on Trade Generics Business:
- faced challenges in Q1 and Q2 because of transition in model
- Minimal price growth compared to the previous year
3 Likes
Cipla Ltd -
Q2 FY 26 results and concall highlights -
Revenues - 7589 vs 7051 cr, up 7.6 pc
EBITDA - 1895 vs 1886 cr, flat YoY ( margins @ 25 vs 27 pc )
Other income - 269 vs 191 cr
PAT - 1353 vs 1305 cr, up 4 pc
Cash on books @ 10368 cr
Debt on books @ 467 cr
Segmental performance -
One India - 3146 cr, up 7 pc. Continue to be the largest player in India by volumes. In respiratory category, company’s brands occupy all of top 5 spots
29 of company’s brands clock sales > 100 cr
Company is ranked in top 5 among five therapeutic categories - Respiratory, Anti Infectives, Urology, Anti Diabetes, Cardiac
Have collaborated with Elli Lilly for marketing and distribution on Mounjaro in India
Other new launches -
Huena - first non anti biotic drug for treatment of urinary track infections ( UTI )
Zemdri - Injectable to treat complicated UTI
Cipenment - In-licenced Enmetazobatum antibiotic from Orchid Pharma
Revenues from OTC products in India in Q2 stood @ 404 cr ( like - Cipladyne, Nicotex, Omnigel, Prolyte, Cofsils )
North America - 2050 cr, up 3 pc ( due currency depreciation, otherwise the revenue would have regrown by 3 pc )
Albuterol is ranked no 1 in US with 22 pc mkt share
Lanreotide mkt share increased to 23 pc in Q2
Launched first Bio Similar - Filgrastim in US
Planning to launch 4 new respiratory ( major ) products in US in CY 26 ( including gAdvair ). Out of these, 3 products will be launched from US facilities
Have got an approval for launch of Glucagon Injection in US ( another key approval )
One Africa - 1180 cr, up 5 pc
Company is ranked No 2 in RSA in Prescriptions + OTC mkt. Have 8 brands in top 30 brands in RSA
Revenues from OTC products stood @ 235 cr
Emerging mkts - 968 cr, up 15 pc
Notes from Concall -
Company’s India branded business grew by 8 pc, the their growth in focus therapies grew in double digits ( like - Anti_diabetes, Urology, Cardiac, Derma ). Company’s share of Chronic business now stands @ a very healthy 62 pc. Their respiratory brand - Forecourt continues to be No 1 selling product in IPM ( by value )
Q3 is generally their stodgiest Qtr for their respiratory portfolio. Their combination products in respiratory portfolio - Foracort G, Ciphaler, Voltido Trio - are gaining strong traction
Company’s trade generics business grew in double digits in Q2 on the back of rigorous distribution execution and new product launches
Revlimid contribution to US sales shall now be coming off sharply ( wef Q3 ). By Q3 or Q4 next year, company shall be back to their current US business’s run rate
Over and above the 04 respiratory launches, 03 peptide launches are also lined up for US in next FY
R&D costs in Q2 stood @ 539 cr, @ 7.2 pc of revenues
Guiding for full yr EBITDA margins of 24 - 25 pc ( vs 26 pc clocked in last FY )
Company believes that launch of Tirzepetide ( in collaboration with Eli Lilly ) should be a sizeable mkt opportunity in Tier 1,2,3 cities. It ll be launched by the company under the brand name - Yurpeak. Cipla shall be their only nationwide partner. Tirzepetide’s patent expiry is post 2030
Given company’s diversification into Urology, Cardio, Anti Diabetic and Derma therapies - growth in India branded business should pick up and company should be able to beat the mkt growth rates over medium to long term
Company expects their Lanreotide mkt share in US to keep inching up over the next 1 yr ( as their capacity comes online ). They aim to take their share to 30 pc levels or thereabouts
Company aspires to clock $ 1 billion sales from US mkts in FY 27 ( despite the loss of sales from Revlimid )
Disc: not holding, posted only for educational purposes, not a buy/sell recommendation, not SEBI registered
Cipla Q3 FY 26 concall highlights -
Revenues - 7074 vs 7073 cr, flat YoY
EBITDA - 1255 vs 1989 cr, down 36 pc
PAT - 674 vs 1575 cr, down 57 pc ( greater fall in PAT is also due an exceptional one time charge of 276 cr - taken up due to implementation of new labour laws )
Cash on books @ 10718 on 31 Dec 25 vs 9413 cr on 31 Dec 24
R&D expenses stood @ 494 cr @ 7 pc of company’s revenues - very healthy R&D spends
Geography wise business highlights -
India business -
Sales @ 3466 cr ( representing 49 pc of company sales )
Branded generics grew by 10 pc
Therapies that outgrew IPM in Q3 include - cardiac, anti-diabetes, respiratory, urology and anti-infectives
Strong growth also seen in OTC and Trade generics business
30 of company’s brands clock sales > 100 cr. In addition 2 trade generic products also clock sales > 100 cr
Company launched 8 products in Trade generics segment in Q3 ( including entry into sexual wellness space )
Company is ranked in top 5 among five therapeutic categories - Respiratory, Anti Infectives, Urology, Anti Diabetes, Cardiac
Foracort continues to be No 1 brand by value in IPM
Have collaborated with Elli Lilly for marketing and distribution on Mounjaro in India
Company believes that launch of Tirzepetide ( basically Mounjaro ) should be a sizeable mkt opportunity in Tier 1,2,3 cities. It ll be launched by the company under the brand name - Yurpeak. Cipla shall be their only nationwide partner. Tirzepetide’s patent expiry is post 2030
Cipla - Pfizer deal -
Cipla to exclusively market and distribute Pfizer’s key brands (Corex, Dolonex, Neksium, Dalacin C) in India
Reinforces Cipla’s position in Acute therapy with trusted brands across Respiratory, Pain, Gastrointestinal, and Anti-infective segments
Leverages Cipla’s deep distribution network to expand access and drive growth without upfront investment
Cipla acquired Inzpera ( in domestic mkt for 115 cr ) -
Cipla acquires 100% stake in Inzpera Healthsciences, adding a differentiated paediatric and wellness portfolio
Combines Inzpera’s portfolio with Cipla’s strong distribution network to accelerate growth and scalability
Positions Cipla to capture rising demand in paediatric care, driving long-term value creation
Other new launches in FY 26 -
Huena - first non anti biotic drug for treatment of urinary track infections ( UTI )
Zemdri - Injectable to treat complicated UTI
Cipenment - In-licenced Enmetazobatum antibiotic from Orchid Pharma
US business -
Contributed to 21 pc of company sales @ 1476 cr
Albuterol ranked No. 1 with total market1 share at 22% (50 million+ inhaler units supplied to the U.S. market
cumulatively)
Lanreotide manufacturing is temporarily paused following USFDA observations at our partner Pharmathen’s facility; re-supply is expected in H1 FY27
gRevlimid had a small contribution in U.S. revenues this quarter
Upcoming launches are expected to cushion this decline and provide long term growth
Upcoming launches in US in FY 27 include - 4 respiratory assets ( including gAdvair ) and 4 peptide launches
South Africa business -
Clocked revenues of 665 cr, up 8.7 pc. Total African sales stood @ 985 cr
Have 7 brands among top 30 brands in RSA
EMs + Europe -
Contributed to 13 pc of company sales @ 919 cr
API sales -
Stood @ 140 cr representing 2 pc of company sales
Notes form Q3 concall -
Sales were flat YoY despite the expected sharp fall in Revlimid sales
In India branded business - Respiratory therapy grew 11 pc, Cardiac and Anti Diabetes grew by 13 pc each, Urology grew by 15 pc
Share of sales from chronic therapies continues to be at 62 pc
22 of company’s brands are in IPM’s top 300 brands
Launched Afrezza in India in Q3 - first inhaled, rapid acting Insulin. Also launched Yurpeak ( Mounjaro ) in India
Nicotex, Cipladyne and Omnigel continue to be No1 brand in their respective segment
Ex-Revlimid, company’s US business grew in double digits
Lanreotide is a key asset for the company ( in US ) - expecting the supplies to begin in Q1/Q2 of next FY ( till then, supplies shall remain constrained ). Also exploring alternative manufacturing sites for this product
Out of 4 respiratory assets that the company is talking about, 3 of them should be fairly large opportunities ( should be able to easily make up for lost sales from Revlimid )
Don’t foresee any delays in the 4 respiratory + 4 peptide asset launches that the company is talking about. Respiratory launches shall happen from company’s India + US sites. Peptide launches are scheduled from company’s partners sites
Guiding for full FY 26’s EBITDA margins @ 21 pc - primarily due loss of Revlimid sales + temporary disruptions in Lanreotide ( vs 26 and 24 pc in FY 25 and FY 24 )
Going forward - R&D expenses should moderate towards 5-5.5 pc of sales ( over next 12 months or so )
Paid 1100 cr to Novartis in Q3 for perpetual license of manufacturing and selling Galvus and combination products ( basically Vildagliptin and its combinations )
Since Lanreotide sales are not going to be available in Q4 as well, sales momentum in US should also remain tepid
Two big respiratory + 2 smaller peptide launches shall happen in H1 next FY. Third big respiratory launch ( Symbicort ) + 1 big peptide launch should happen in H2 next FY
In-Licensed products contribute to < 10 pc of India branded sales. Launch of Terzapetide shall further growth in this product portfolio
Looking at a second site for Lanreotide to de-risk company’s supply chain
For the first two respiratory products expected to be launched in H1 next yr, company shall be the only generic supplier for a decent period of time
Company won’t be launching Semaglutide generic in the first wave in Indian mkts
Disc: hold a small tracking position, not SEBI registered, not a buy/sell recommendation, posted only for educational purposes
Article by The Morning context highlights its cash position and R&D spends but questions the non- aggressiveness in pursuing growth opportunities and inorganic acquisitions. No major drug acquisitions, not getting into Semaglutide production consciously, Lupin on its tail in respiratory drugs and reliance on US sales with no major blockbuster drug- some major pressing questions Cipla has to mitigate.
1 Like
quick update on Cipla Q1 FY27 from the recent earnings call:
revenue came in at highest ever Q1 of ₹7,119 cr (+2.3% yoy reported). one India (combined india business) reported ₹3,452 Cr (+12% YoY), with branded prescription growing 15.4%.
generic ventolin (cipla’s generic version of the albuterol inhaler) has been commercially launched in the US with CGT exclusivity. management said this is part of the North America launch bridge.
ebitda margin dropped to 16.7% (from 25.6% last year). management said this is not the steady state margin and attributed it to war related costs, inventory write off and pre launch investments. they have reaffirmed fy27 ebitda guidance of 18.5–20% and the $1 billion north america exit-run rate target.
few points from the call:
- on advair(another respiratory inhaler), management said it will face 3-4 competitors and will not be a $100 mn+ opportunity.
- lanreotide continues to remain excluded from guidance, with no clear timeline given. (cipla was supplying lanreotide in the US but supply got disrupted because of issues at their partner’s manufacturing facility).
not a recommendation. just sharing for discussion.
1 Like